Who: Amgen, Inc.; Generate Biomedicines
What: Amgen and Flagship Pioneering-backed Generate announced a deal 6 January across different disease areas and modalities, using Generate’s artificial...
Amgen Joins AI/ML Gold Rush With Generate Deal
Deal Snapshot: At a same-day conference, Amgen’s CEO outlined the importance of AI/ML to the company’s drug development strategy, as numerous large biopharma companies have recently made similar deals.
More from AI
• By
CEO Robert Bradway expressed support on the company’s Q2 earnings call for lower drug prices but said it was “premature” to comment in detail on particular proposals.
• By
While South Korea's biopharma sector has made progress in its digital transformation, including the adoption of AI technologies, a recent report has identified multiple remaining challenges.
• By
As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?
• By
Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
More from Digital Technologies
• By
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
• By
A new study by Tufts CSDD performed a deep dive into use of decentralized clinical trial techniques, but one of the study’s authors said DCTs have been dialed back.
• By
Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.